Cargando…
Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion
BACKGROUND: Angiotensin converting enzyme inhibitors are routinely prescribed to patients with chronic kidney disease because of their known renoprotective effects. We evaluated the effect of short-term therapy with the angiotensin converting enzyme inhibitor, enalapril, in early Alport syndrome, de...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65703/ https://www.ncbi.nlm.nih.gov/pubmed/11869456 http://dx.doi.org/10.1186/1471-2369-3-2 |
_version_ | 1782120176895918080 |
---|---|
author | Adler, Liora Mathew, Roy Futterweit, Stephen Frank, Rachel Gauthier, Bernard G Kashtan, Clifford E Trachtman, Howard |
author_facet | Adler, Liora Mathew, Roy Futterweit, Stephen Frank, Rachel Gauthier, Bernard G Kashtan, Clifford E Trachtman, Howard |
author_sort | Adler, Liora |
collection | PubMed |
description | BACKGROUND: Angiotensin converting enzyme inhibitors are routinely prescribed to patients with chronic kidney disease because of their known renoprotective effects. We evaluated the effect of short-term therapy with the angiotensin converting enzyme inhibitor, enalapril, in early Alport syndrome, defined as disease duration less than 10 years and a normal glomerular filtration rate. METHODS: 11 children with early Alport syndrome were investigated. Two consecutive early morning urine specimens were collected at the start of the study for measurement of urinary creatinine, total protein, albumin, TGF-β, and nitrite excretion. Patients were treated with enalapril, ≅ 0.2 mg/kg/day, once a day for 14 days. Two early morning urine specimens were collected on days 13 and 14 of enalapril treatment and two weeks later for measurement of urinary creatinine, total protein, albumin, TGF-β, and nitrite excretion. RESULTS: Prior to treatment, urinary excretion of transforming growth factor-β and nitrite, the major metabolite of nitric oxide, was within normal limits in all patients. Administration of enalapril for 2 weeks did not alter urinary albumin, transforming growth factor-β, or nitrite excretion. CONCLUSION: These findings suggest that early Alport syndrome represents a disease involving exclusively intrinsic glomerular barrier dysfunction. At this stage of the illness, there is no evidence of angiotensin II-mediated proteinuria or increased production of transforming growth factor-β and, therefore, routine treatment with an angiotensin converting enzyme inhibitor may not be warranted. |
format | Text |
id | pubmed-65703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-657032002-02-28 Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion Adler, Liora Mathew, Roy Futterweit, Stephen Frank, Rachel Gauthier, Bernard G Kashtan, Clifford E Trachtman, Howard BMC Nephrol Research Article BACKGROUND: Angiotensin converting enzyme inhibitors are routinely prescribed to patients with chronic kidney disease because of their known renoprotective effects. We evaluated the effect of short-term therapy with the angiotensin converting enzyme inhibitor, enalapril, in early Alport syndrome, defined as disease duration less than 10 years and a normal glomerular filtration rate. METHODS: 11 children with early Alport syndrome were investigated. Two consecutive early morning urine specimens were collected at the start of the study for measurement of urinary creatinine, total protein, albumin, TGF-β, and nitrite excretion. Patients were treated with enalapril, ≅ 0.2 mg/kg/day, once a day for 14 days. Two early morning urine specimens were collected on days 13 and 14 of enalapril treatment and two weeks later for measurement of urinary creatinine, total protein, albumin, TGF-β, and nitrite excretion. RESULTS: Prior to treatment, urinary excretion of transforming growth factor-β and nitrite, the major metabolite of nitric oxide, was within normal limits in all patients. Administration of enalapril for 2 weeks did not alter urinary albumin, transforming growth factor-β, or nitrite excretion. CONCLUSION: These findings suggest that early Alport syndrome represents a disease involving exclusively intrinsic glomerular barrier dysfunction. At this stage of the illness, there is no evidence of angiotensin II-mediated proteinuria or increased production of transforming growth factor-β and, therefore, routine treatment with an angiotensin converting enzyme inhibitor may not be warranted. BioMed Central 2002-02-14 /pmc/articles/PMC65703/ /pubmed/11869456 http://dx.doi.org/10.1186/1471-2369-3-2 Text en Copyright © 2002 Adler et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Research Article Adler, Liora Mathew, Roy Futterweit, Stephen Frank, Rachel Gauthier, Bernard G Kashtan, Clifford E Trachtman, Howard Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion |
title | Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion |
title_full | Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion |
title_fullStr | Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion |
title_full_unstemmed | Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion |
title_short | Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-β, and nitrite excretion |
title_sort | angiotensin converting enzyme inhibitor therapy in children with alport syndrome: effect on urinary albumin, tgf-β, and nitrite excretion |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65703/ https://www.ncbi.nlm.nih.gov/pubmed/11869456 http://dx.doi.org/10.1186/1471-2369-3-2 |
work_keys_str_mv | AT adlerliora angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion AT mathewroy angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion AT futterweitstephen angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion AT frankrachel angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion AT gauthierbernardg angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion AT kashtanclifforde angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion AT trachtmanhoward angiotensinconvertingenzymeinhibitortherapyinchildrenwithalportsyndromeeffectonurinaryalbumintgfbandnitriteexcretion |